IGF2BP3 and leukemia: The depletion of IGF2BP3 results in to decreased expression of both full‐length variants and alternatively spliced variants (shorter variant) for Cd69, Hoxa7 and Hoxa9, suggesting that IGF2BP3 serves as a critical regulator and a potential therapeutic target for MLL‐Af4‐driven leukaemia.127